BioNTech SE
(NASDAQ: BNTX)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $79.86 | Change: +1.10 | %Change: +1.40% | Volume: 593,951 |
Open: | $ 79.65 | Volume: | 593,951 | |
---|---|---|---|---|
High: | $ 81.50 | Yield(%) | 0.00 | |
Low: | $ 79.38 | P/E Ratio (ttm): | 153.17 | |
Dividend ($): | 1.55 | Market Cap ($): | 18.72B | |
EPS ($) | 0.51 | Shares Out: | 237.73M |
% Price Change (last 4 weeks): | -20.83 |
---|---|
% Price Change (last 13 weeks): | -13.95 |
% Price Change (last 26 weeks): | -29.89 |
% Price Change (last 52 weeks): | -26.95 |
% Price Change (year to date): | -25.37 |
Return on Equity (%): | 4.60 |
---|---|
Return on Assets (%): | 4.00 |
Return on Invested Capital (%): | 35.40 |
Gross Profit Margin (%): | 85.01 |
---|---|
Net Profit Margin (%): | 24.36 |
Operating Profit Margin (%): | 23.72 |
|
|
50-day Moving Average: | $91.71 |
---|---|
200-day Moving Average: | $96.43 |
Avg. Daily Vol. (last 50 days): | 769,332 |
Avg. Daily Vol. (last 200 days): | 704,747 |
52-wk high: | $125.83 |
52-wk low: | $78.02 |
Bid: | $79.18 |
Ask: | $81.47 |
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
|
BioNTech SE
An der Goldgrube 12 Mainz RP 55131 Phone: 49.6131.9084.0 Fax: n/a http://www.biontech.de |
Earnings (1year) ($): | 0.51 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | 153.17 |
Book Value ($): | 94.08 |
Cash Flow ($): | 5.06 |
Price/Earnings (x): | 153.17 |
---|---|
Price/Sales (x): | 6.20 |
Price/Book (x): | 1.12 |
Price/Cash Flow (x): | 4.41 |
Quick Ratio (x): | 9.26 |
---|---|
Current Ratio (x): | 9.43 |
LT Debt/Equity (x): | 0.94 |
Total Debt/Equity (x): | 1.08 |